INCOBOTULINUMTOXINA
Post-stroke
Parc de Salut Marprotein_peptidePhase 4 / ApprovedDormant
BBB
78/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 66/ 100
- Competitive Position
- 95/ 100
Competitive context
133 Active assets in the Post-stroke cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aggrenox Boehringer Ingelheim | Phase 4 | BBB |
ATENOLOL Northern California Institute of Research and Education | Phase 4 | BBB |
Dextromethorphan University of Florida | Phase 4 | BBB |
Rivaroxaban China National Center for Cardiovascular Diseases | Phase 4 | BBB |
Tenecteplase Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
INCOBOTULINUMTOXINA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →